WHO WE ARE
AIVITA Biomedical is a biotechnology company developing personalized vaccines for the prevention of COVID-19 and treatment of cancer. We take a unique pan-antigenic approach for our cancer vaccine — targeting all neoantigens, rather than a select few — allowing our treatment to overcome cancer’s tendency to mutate over time. Utilizing our autologous cell therapy platform, which has generated multiple therapeutic vaccine programs shown to be safe and effective in early clinical trials, we are developing a personalized vaccine for with adaptive immunity against COVID-19. Our unique expertise in stem cell growth and directed, high-purity differentiation enables us to develop safe, efficient and economical manufacturing processes for therapeutic development.
Our patient-specific treatments in cancer have shown tremendous promise in eradicating tumors without harmful side effects in our melanoma, glioblastoma and ovarian cancer clinical studies. Our personalized vaccine for COVID-19 is currently being evaluated in clinical studies in Indonesia in collaboration with Indonesia Ministry of Health and is being prepared for potential clinical investigation in the United States. We have also leveraged our approach to create a proprietary skincare line, which dedicates 100 percent of net proceeds towards advancing revolutionary treatments for patients with cancer. We explore additional applications in human health, including vision loss.